Verrica Pharmaceuticals Inc. VRCA

– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration – WEST CHESTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will present posters on a new analysis of Phase 3 trials of

– Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration – WEST CHESTER, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will present posters on YCANTH® (VP-102), a therapy approved by the FDA

WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 28th Annual Global Investment Conference. H.C. Wainwright 28th Annual Global Investment ConferenceEvent d

The COVE-2 trial follows a previously completed Phase II trial that had shown a decline in the number of common warts.

– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment – – Second pivotal Phase 3 trial (COVE-3) has already exceeded 50% of current target enrollment, with topline data currently expected in mid-2027 – WEST CHESTER, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological disea

– Company reports record demand for YCANTH® as dispensed applicator units grew to 19,626 in Q2 2026, up 28.3% over the previous quarter and 46.1% year-over-year – – Topline data from global Phase 3 program studying common warts currently expected in mid-2027 – – The Company’s cash runway could extend into 2028 based on its current operating plan and assuming full availability of its new credit facility – – Company reports total revenue of $5.9 million in Q2 2026, including U.S. YCANTH net produc

— Facility will support YCANTH® commercialization, global Phase 3 program for YCANTH® in common warts and general corporate operations — — Facility provides potential for no scheduled interest or principal payments until maturity in December 2030 — — Facility provided by an entity controlled by Paul B. Manning, Verrica’s Chairman and largest shareholder — WEST CHESTER, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics

WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss the Company's financial results for the second quarter ending June 30, 2026, and provide a corporate update. Ind

WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced an exclusive distribution, marketing and supply agreement (“the Agreement”) granting Medomie Pharma Ltd. (“Medomie”) rights to seek regulatory approval for and distribute YCANTH® for the treatment of molluscum contagiosum (“molluscum”) in

– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan – – Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan, including common warts – WEST CHESTER, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatol

WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference. Jefferies Global Healthcare Conference, June 2-4, 2026Event details:Date: Thursday,

Moby summary of Verrica Pharmaceuticals Inc.'s Q1 2026 earnings call

On Tuesday, Verrica Pharmaceuticals (NASDAQ:VRCA) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. Access the full call at https://viavid.webcasts.com/starthere.jsp?ei=1758586&tp_key=307852c58b Summary Verrica Pharmaceuticals Inc reported a total revenue of $5 million for Q1 2026,

Verrica Pharmaceuticals Inc (VRCA) reports significant revenue growth and strategic milestones, despite facing financial and operational hurdles.